Sadie Stern Sells 4,137 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 4,137 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $140.00, for a total transaction of $579,180.00. Following the transaction, the executive vice president now directly owns 76,304 shares in the company, valued at approximately $10,682,560. The transaction was disclosed in a filing with the SEC, which is available through this link.

Sadie Stern also recently made the following trade(s):

• On Tuesday, March 12th, Sadie Stern sold 20,321 shares of DexCom stock. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81.
• On Tuesday, January 16th, Sadie Stern sold 2,902 shares of DexCom stock. The shares were sold at an average price of $123.63, for a total transaction of $358,774.26.

DexCom Trading Down 0.3 %

Shares of DXCM stock opened at $139.48 on Thursday. The company has a 50 day moving average of $125.31 and a 200-day moving average of $111.84. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00. The firm has a market cap of $53.77 billion, a P/E ratio of 106.47, a PEG ratio of 2.41 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. DexCom’s quarterly revenue was up 26.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.34 EPS. Sell-side analysts anticipate that DexCom, Inc. will post 1.76 earnings per share for the current year.

Wall Street Analyst Weigh In

DXCM has been the topic of several recent research reports. Royal Bank of Canada began coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. Raymond James increased their price objective on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 23rd. Morgan Stanley increased their price objective on shares of DexCom from $101.00 to $122.00 and gave the company an “equal weight” rating in a research note on Monday, December 4th. Piper Sandler increased their price objective on shares of DexCom from $135.00 to $150.00 and gave the company an “overweight” rating in a research note on Tuesday, December 19th. Finally, Wells Fargo & Company increased their price objective on shares of DexCom from $110.00 to $136.00 and gave the company an “overweight” rating in a research note on Wednesday, December 13th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $136.67.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Bartlett & CO. Wealth Management LLC bought a new position in DexCom in the 4th quarter worth approximately $27,000. DSM Capital Partners LLC bought a new position in DexCom in the 4th quarter worth approximately $28,000. Valley National Advisers Inc. boosted its holdings in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares during the period. Harbour Investments Inc. boosted its holdings in DexCom by 55.6% in the 3rd quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock worth $31,000 after buying an additional 120 shares during the period. Finally, Atlas Capital Advisors LLC bought a new position in DexCom in the 2nd quarter worth approximately $33,000. 97.75% of the stock is owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.